Compare KNX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNX | ROIV |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 20.7B |
| IPO Year | 2010 | 2021 |
| Metric | KNX | ROIV |
|---|---|---|
| Price | $55.65 | $26.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $61.17 | $27.56 |
| AVG Volume (30 Days) | 2.8M | ★ 4.4M |
| Earning Date | 04-22-2026 | 02-06-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $7,469,689,000.00 | $29,053,000.00 |
| Revenue This Year | $5.92 | N/A |
| Revenue Next Year | $7.91 | $594.84 |
| P/E Ratio | $135.38 | ★ N/A |
| Revenue Growth | ★ 0.80 | N/A |
| 52 Week Low | $36.69 | $8.73 |
| 52 Week High | $64.10 | $30.33 |
| Indicator | KNX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 42.52 |
| Support Level | $54.53 | $20.46 |
| Resistance Level | $63.15 | $27.94 |
| Average True Range (ATR) | 1.96 | 0.88 |
| MACD | 0.15 | -0.38 |
| Stochastic Oscillator | 49.74 | 1.04 |
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.